Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis

Zhang, Wenyan; Xu, Shuoyan; Yu, Hongmei; Li, Xuena; Jin, Zhuangzhuang; Li, Yaming; He, Zhiyi

doi:10.1007/s12149-020-01566-4

Cited by 4 publications

(1 citation statement)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tau pathology can be in vivo visualized and quantified using positron emission tomography (PET) with ligands affine to NFTs [ 4 , 5 ]. Among several radioligands developed so far, [ 18 F]Flortaucipir showed high sensitivity and specificity to AD-related NFTs [ 6 , 7 ], and represents the first and, to date, the only tau PET tracer approved by the U.S.A. Food and Drug Administration to support the diagnosis in patients with suspected AD [ 8 , 9 ]. [ 18 F]Flortaucipir uptake correlates with histological findings of AD-related tau pathology [ 10 – 12 ], with phosphorylated tau (p-tau 181 ) in the cerebral spinal fluid (CSF) [ 13 , 14 ], discriminates between preclinical AD and AD-related dementia (ADRD) [ 11 , 12 ], and is highly predictive of future cognitive decline and conversion of cognitively normal (CN) and mild cognitive impairment (MCI) to AD [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Unsupervised [18F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease

Quattrini

Ferrari

Pievani

et al. 2023

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Several [18F]Flortaucipir cutoffs have been proposed for tau PET positivity (T+) in Alzheimer’s disease (AD), but none were data-driven. The aim of this study was to establish and validate unsupervised T+ cutoffs by applying Gaussian mixture models (GMM). Methods Amyloid negative (A−) cognitively normal (CN) and amyloid positive (A+) AD-related dementia (ADRD) subjects from ADNI (n=269) were included. ADNI (n=475) and Geneva Memory Clinic (GMC) cohorts (n=98) were used for validation. GMM-based cutoffs were extracted for the temporal meta-ROI, and validated against previously published cutoffs and visual rating. Results GMM-based cutoffs classified less subjects as T+, mainly in the A− CN (<3.4% vs >28.5%) and A+ CN (<14.5% vs >42.9%) groups and showed higher agreement with visual rating (ICC=0.91 vs ICC<0.62) than published cutoffs. Conclusion We provided reliable data-driven [18F]Flortaucipir cutoffs for in vivo T+ detection in AD. These cutoffs might be useful to select participants in clinical and research studies.

show abstract